RxDoctor Payments Data

Judith Kirby

Ophthalmology · Dallas, TXNPI 1720291859

Payments from drug & device makers

$4,101in general payments, 2019–2025

Across 152 payments — averaging $26.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$547
  • Notal Vision, Inc.$405
  • Sun Pharmaceutical Industries Inc.$304
  • Rxsight Inc$210
  • Novartis$184
  • plus $1K from 21 others

What the payments were for

  • Speaking & faculty fees$40510%
  • Travel & lodging$120%
  • Food & beverage$3,62488%
  • Education$411%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,101 in reported general payments places this provider in the 65th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$467,762
Medicare patients
939
Services billed
4,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine41$57,527
XiidraLifitegrast52$48,507
Cyclosporine36$26,128
LumiganBimatoprost40$25,409
ProlensaBromfenac Sodium72$24,428
RhopressaNetarsudil Mesylate17$15,178
CombiganBrimonidine Tartrate/Timolol34$10,239
Latanoprost602$7,606
Alphagan PBrimonidine Tartrate16$6,656
Difluprednate66$6,109
Brimonidine Tartrate47$5,811
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol24$4,930
Travoprost19$4,438
MoxifloxacinMoxifloxacin Hcl225$3,784
Timolol Maleate280$3,378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$547$99,830131 claims
Bausch & Lomb Americas Inc.Xiidra$166$48,50752 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$95$24,42872 claims
Aerie Pharmaceuticals, Inc.Rhopressa$156$15,17817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →